Patents by Inventor Himanshu Brahmbhatt

Himanshu Brahmbhatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10799461
    Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: October 13, 2020
    Assignee: ENGENEIC MOLECULAR DELIVERY PTY LTD
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 10583200
    Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 10, 2020
    Assignee: EnGeneIC Molecular Delivery Pty Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20200054689
    Abstract: Compositions and methods for treating cancer are provided. In particular, the compositions comprise an anti-neoplastic agent and either an interferon type I agonist or an interferon type II agonist, or a combination of an interferon type I agonist and an interferon type II agonist.
    Type: Application
    Filed: July 22, 2019
    Publication date: February 20, 2020
    Applicant: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid
  • Patent number: 10500277
    Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: December 10, 2019
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 10441546
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: October 15, 2019
    Assignee: EnGenelC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Patent number: 10426736
    Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 1, 2019
    Assignee: ENGENEIC MOLECULAR DELIVERY PTY. LTD.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 10383827
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 20, 2019
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Publication number: 20190216946
    Abstract: Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages.
    Type: Application
    Filed: March 22, 2019
    Publication date: July 18, 2019
    Applicant: EnGenelC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 10328159
    Abstract: Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 25, 2019
    Assignee: ENGENIC MOLECULAR DELIVERY PTY LTD.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20190091160
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Application
    Filed: October 10, 2018
    Publication date: March 28, 2019
    Applicant: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu BRAHMBHATT, Jennifer MACDIARMID, Toby HULF
  • Publication number: 20180369416
    Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 27, 2018
    Applicant: EnGenelC Molecular Delivery Pty Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 10098847
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 16, 2018
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Publication number: 20180280311
    Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
    Type: Application
    Filed: June 5, 2018
    Publication date: October 4, 2018
    Applicant: EnGenelC Molecular Delivery Pty Ltd
    Inventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid
  • Patent number: 10076545
    Abstract: The present invention provides a method for purifying bacterial minicells that involves subjecting a sample containing minicells to density gradient centrifugation in a biologically compatible medium. The method optionally includes a preliminary differential centrifugation step and one or more filtration steps. The invention also provides a method for purifying bacterial minicells in which a sample containing minicells is subjected to a condition that induces parent bacterial cells to adopt a filamentous form, followed by filtration of the sample to separate minicells from parent bacterial cells. The inventive methods optionally include one or more steps to remove endotoxin from purified minicell preparations, and/or treatment of purified minicell preparations with an antibiotic. Additionally, the invention provides purified minicell preparations, prepared according to the foregoing methods, and containing fewer than about 1 contaminating parent bacterial cell per 107, 108, 109, 1010, or 1011 minicells.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: September 18, 2018
    Assignee: EnGeneIC Molecular Delivery Pty. Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20180250413
    Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
    Type: Application
    Filed: January 28, 2018
    Publication date: September 6, 2018
    Applicant: EnGeneIC Molecular Deliver Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 9987377
    Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 5, 2018
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20180133163
    Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 17, 2018
    Applicant: EnGeneIC Molecular Delivery Pty Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20180100159
    Abstract: This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer.
    Type: Application
    Filed: October 4, 2017
    Publication date: April 12, 2018
    Applicant: EnGenelC Molecular Delivery Pty. Ltd.
    Inventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid
  • Publication number: 20180043027
    Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.
    Type: Application
    Filed: October 23, 2017
    Publication date: February 15, 2018
    Applicant: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu BRAHMBHATT, Jennifer MACDIARMID
  • Publication number: 20180028456
    Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
    Type: Application
    Filed: August 11, 2017
    Publication date: February 1, 2018
    Applicant: EnGeneIC Molecular Delivery Pty. Ltd.
    Inventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid